The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups

Neuropathology and Applied Neurobiology

Volumn 41, Issue 3, 2015, Pages 319-332

  Domingues, Patrícia Henriques ^a,c   Teodósio, Cristina ^a   Otero, Álvaro ^b   Sousa, Pablo ^b   Gonçalves, Jesus Maria ^b   Nieto, Ana Belen ^a   Lopes, Maria Celeste ^c   de Oliveira, Catarina ^c   Orfao, Alberto ^a   Tabernero, Maria Dolores ^a,b  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

CD44; CD53; iFISH; Meningioma; Multiparameter flow cytometry; Protein expression profile

Indexed keywords

CD14 ANTIGEN; CD2 ANTIGEN; CD38 ANTIGEN; CD53 ANTIGEN; CD59 ANTIGEN; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HLA A1 ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MICROSOMAL AMINOPEPTIDASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BCL 2; SOMATOMEDIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MONOSOMY; MULTIPARAMETER FLOW CYTOMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; TUMOR CELL; CELL SEPARATION; CHROMOSOME ANALYSIS; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL SEPARATION; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; YOUNG ADULT;

EID: 84924025974     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12127     Document Type: Article

References (52)

1. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A. Meningiomas. In WHO Classification of Tumours of the Central Nervous Syste, 4th edn. Eds Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Lyon, France: IARC Press, 2007; 164-172
2. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006; 5: 1045-1054
3. Domingues PH, Sousa P, Otero A, Goncalves JM, Ruiz L, Lopes MC, de Oliveira C, Orfao A, Tabernero MD. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro-oncol 2014. doi: 10.1093/neuonc/not325 [Epub ahead of print]
4. Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, Sousa P, Lara M, Tabernero MD. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro-oncol 2007; 9: 438-446
5. Tabernero MD, Espinosa AB, Maillo A, Sayagues JM, Alguero Mdel C, Lumbreras E, Diaz P, Goncalves JM, Onzain I, Merino M, Morales F, Orfao A. Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features. Am J Clin Pathol 2005; 123: 744-751
6. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A. Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol 2009; 19: 409-420
7. Espinosa AB, Tabernero MD, Maillo A, Sayagues JM, Ciudad J, Merino M, Alguero MC, Lubombo AM, Sousa P, Santos-Briz A, Orfao A. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 2006; 12: 772-780
8. Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, Maillo A, Barcena P, Garcia-Macias MC, Lopes MC, de Oliveira C, Orfao A, Tabernero MD. Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 2012; 181: 1749-1761
9. Paz-Bouza JI, Orfao A, Abad M, Ciudad J, Garcia MC, Lopez A, Bullon A. Transrectal fine needle aspiration biopsy of the prostate combining cytomorphologic, DNA ploidy status and cell cycle distribution studies. Pathol Res Pract 1994; 190: 682-689
10. Cruz I, Ciudad J, Cruz JJ, Ramos M, Gomez-Alonso A, Adansa JC, Rodriguez C, Orfao A. Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol 2005; 123: 66-74
11. Matarraz S, Fernandez C, Albors M, Teodosio C, Lopez A, Jara-Acevedo M, Cervero C, Caballero G, Gutierrez O, Orfao A. Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis. Cytometry B Clin Cytom 2011; 80: 354-361
12. Tabernero MD, Espinosa AB, Maillo A, Rebelo O, Vera JF, Sayagues JM, Merino M, Diaz P, Sousa P, Orfao A. Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist 2007; 12: 1225-1236
13. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 2004; 108: 930-936
14. Ravindranath NM, Shuler C. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 231-239
15. Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother 2006; 55: 987-995
16. Shamah SM, Alberta JA, Giannobile WV, Guha A, Kwon YK, Carroll RS, Black PM, Stiles CD. Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res 1997; 57: 4141-4147
17. Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 2001; 8 (Suppl. 1): 49-53
18. Mosnier JF, Perret AG, Brunon J, Boucheron S. Expression of the bcl-2 oncoprotein in meningiomas. Am J Clin Pathol 1996; 106: 652-659
19. Roessler K, Dietrich W, Kitz K. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas. Neurosurg Rev 1999; 22: 205-209
20. Tyagi D, Sharma BS, Gupta SK, Kaul D, Vasishta RK, Khosla VK. Expression of Bcl2 proto-oncogene in primary tumors of the central nervous system. Neurol India 2002; 50: 290-294
21. Funa K, Sasahara M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J Neuroimmune Pharmacol 2013; doi: 10.1007/s11481-013-9479-z
22. Doucette T, Yang Y, Zhang W, Fuller GN, Suki D, Fults DW, Rao G. Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer 2011; 129: 2093-2103
23. Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 2008; 14: 361-371
24. Mawrin C, Wolke C, Haase D, Kruger S, Firsching R, Keilhoff G, Paulus W, Gutmann DH, Lal A, Lendeckel U. Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. Brain Pathol 2010; 20: 200-210
25. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999; 5: 237-241
26. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005; 6: 801-811
27. Ovalle S, Gutierrez-Lopez MD, Olmo N, Turnay J, Lizarbe MA, Majano P, Molina-Jimenez F, Lopez-Cabrera M, Yanez-Mo M, Sanchez-Madrid F, Cabanas C. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 2007; 121: 2140-2152
28. Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T, Nishino K, Goto H, Yoneda T, Kumagai T, Osaki T, Hayashi S, Aozasa K, Kawase I. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 2003; 22: 674-687
29. Mazzocca A, Liotta F, Carloni V. Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. Gastroenterology 2008; 135: 244-256
30. Hirano C, Nagata M, Noman AA, Kitamura N, Ohnishi M, Ohyama T, Kobayashi T, Suzuki K, Yoshizawa M, Izumi N, Fujita H, Takagi R. Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer 2009; 124: 2911-2916
31. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003; 284: 78-88
32. Sorkin A. Internalization of the epidermal growth factor receptor: role in signalling. Biochem Soc Trans 2001; 29: 480-484
33. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I. Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest 2009; 27: 691-698
34. Wickremesekera A, Hovens CM, Kaye AH. Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci 2010; 17: 1155-1158
35. Mahzouni P, Movahedipour M. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. Pathol Res Pract 2012; 208: 221-224
36. Stamenkovic I, Yu Q. Merlin, a 'magic' linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 2010; 11: 471-484
37. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001; 15: 968-980
38. Tabernero MD, Maillo A, Nieto AB, Diez-Tascon C, Lara M, Sousa P, Otero A, Castrillo A, Patino-Alonso Mdel C, Espinosa A, Mackintosh C, de Alava E, Orfao A. Delineation of commonly deleted chromosomal regions in meningiomas by high-density single nucleotide polymorphism genotyping arrays. Genes Chromosomes Cancer 2012; 51: 606-617
39. Tabernero M, Jara-Acevedo M, Nieto AB, Caballero AR, Otero A, Sousa P, Goncalves J, Domingues PH, Orfao A. Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas. BMC Med Genet 2013; 14: 114
40. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339: 1077-1080
41. Lewy-Trenda I, Omulecka A, Janczukowicz J, Papierz W. CD44 expression in human meningiomas: an immunohistochemical analysis. Pol J Pathol 2004; 55: 33-37
42. Ruiz J, Martinez A, Hernandez S, Zimman H, Ferrer M, Fernandez C, Saez M, Lopez-Asenjo JA, Sanz-Ortega J. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol 2010; 25: 341-349
43. Lagaudriere-Gesbert C, Le Naour F, Lebel-Binay S, Billard M, Lemichez E, Boquet P, Boucheix C, Conjeaud H, Rubinstein E. Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. Cell Immunol 1997; 182: 105-112
44. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001; 54: 227-229
45. Lichtor T, Kurpakus MA, Gurney ME. Expression of insulin-like growth factors and their receptors in human meningiomas. J Neurooncol 1993; 17: 183-190
46. Wick MR. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol 2008; 12: 72-84
47. Ishizawa K, Komori T, Shimada S, Hirose T. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol 2008; 27: 118-128
48. Renshaw AA. O13 (CD99) in spindle cell tumors: reactivity with hemangiopericytoma, solitary fibrous tumor, synovial sarcoma, and meningioma but rarely with sarcomatoid mesothelioma. Appl Immunohistochem 1995; 3: 250-256
49. Vaz R, Borges N, Cruz C, Azevedo I. Cerebral edema associated with meningiomas: the role of peritumoral brain tissue. J Neurooncol 1998; 36: 285-291
50. Arismendi-Morillo G, Castellano A. Tumoral micro-blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study. J Neurooncol 2005; 73: 211-217
51. Brown RC, Davis TP. Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke 2002; 33: 1706-1711
52. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45: 285-289